Investigators assessed the impact of multimodal anesthesia on opioid use among patients undergoing coronary artery bypass graft or valve surgery.

OPNT003 is an intranasal formulation containing the high affinity opioid antagonist, nalmefene.

Investigators in the US sourced data for this study from the National Survey on Drug Use and Health collected between 2015 and 2019.

Electronic health records from 77 health care organizations in the US were evaluated for a risk for endocarditis among patients with opioid use disorder or cocaine use disorder on the basis of contracting COVID-19.

A team of investigators conducted a study in an attempt to identify factors that predict the risk of developing opioid use disorder following receipt of a first opioid prescription.

Investigators sourced data for this study from Veteran’s Affairs claims.

Investigators report findings from the AVOID-2 trial that evaluated outcomes following prehospital administration of lidocaine or fentanyl for pain associated with STEMI.

Investigators conducted a cohort study to assess the impact of opioid and stimulant use disorder on risk for overdose among a population of previously incarcerated individuals.

Researchers investigated whether buprenorphine use was associated with a lower risk for adverse neonatal outcomes compared with methadone during pregnancy.

RiVive is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.